Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.

Ayodele AlabiKossiwa KokouSaidou MahmoudouRanmali KavishnaSravya S NakkaSylvia RothenbergerFungai P MusangomuneiBisola F OlubiyiJuste C Bie-OndoAnita L KabwendeThirumalaisamy P Velavannull nullDonata MedagliniHelder I NakayaOlivier EnglerAli M HarandiClaire-Anne SiegristPeter G KremsnerSelidji T Agnandji

Published in: The Journal of infection (2024)

The replication and shedding do not affect the favourable risk-benefit balance of the rVSVΔG-ZEBOV-GP in children.

Keyphrases

open label
study protocol
young adults
clinical trial
phase iii
phase ii
emergency department
rectal cancer